OrthodontiCell, Inc. has secured sufficient capital to complete the remaining testing required to support its application to begin a planned Phase II pivotal clinical study in the United States. The announcement, made by the company, marks a critical step in the development of its bioelectric technology designed to accelerate tooth movement during orthodontic treatment. The funding allows the company to finish the necessary testing and prepare a regulatory submission seeking authorization to initiate the planned final pivotal U.S. study.
The proposed study is intended to evaluate the safety and effectiveness of the technology, including its potential to reduce the time required to straighten teeth. If successful, this could significantly shorten orthodontic treatment duration, addressing a major patient concern. The company’s approach focuses on using controlled bioelectric stimulation alongside orthodontic care, aiming to improve the overall patient experience. With capital now in place for this stage, OrthodontiCell can focus on completing the testing and advancing its regulatory application. Final study design, participating centers, and enrollment timing will be announced in the near future as the program progresses.
“For patients and families, a shorter path to a healthy, confident smile can make a meaningful difference,” said Mark Terrill, CEO. “Securing the capital to complete this testing moves OrthodontiCell closer to its next clinical milestone and gives our team the resources to advance the application process.” The capital secured covers the remaining testing supporting the planned application, while funding for conducting the pivotal study itself will be addressed separately.
This development is important because it signals progress toward a potential new option in orthodontics that could reduce treatment time, a key factor for patients considering braces or aligners. The technology, developed by OrthodontiCell, remains investigational, and initiation of the planned U.S. study is subject to completion of testing and applicable regulatory and ethics approvals. The company’s forward-looking statements reflect current expectations, though actual results and timing may differ. If the planned pivotal study confirms safety and effectiveness, OrthodontiCell’s bioelectric approach could become a valuable adjunct to orthodontic treatment, potentially transforming the patient experience by offering faster results.
The securing of capital also underscores investor confidence in the company’s technology and its potential to address an unmet need in orthodontics. While the path to regulatory approval and commercialization remains lengthy, this funding enables the next crucial step. The orthodontic industry has long sought ways to accelerate tooth movement without compromising safety, and bioelectric stimulation represents a novel approach. As OrthodontiCell moves forward, the results of its planned pivotal study will be closely watched by clinicians, patients, and investors alike. For now, the company’s ability to complete the required testing brings it closer to its goal of initiating the U.S. pivotal study, a major milestone in the development of any new medical device.


